Is 15 mg in 2 mL of phosphate-buffered diluent a sensible presentation for orforglipron?

The particulars: 15 mg · 2 mL · phosphate-buffered diluent · orforglipron.

I would like to define my thresholds before I have a result, for obvious reasons.

I want a plan with explicit stopping rules, not just steps.

What is the minimum version of this that is still defensible?

The short version: more diluent means a lower concentration, a larger volume per dose and a finer reading; less means the opposite.

Worked example. A 10 mg vial reconstituted with 2 mL gives 5 mg/mL. A 0.5 mg dose is 0.5 ÷ 5 = 0.1 mL, which on a U-100 syringe is 10 units. Reconstitute the same vial with 1 mL and the concentration doubles to 10 mg/mL, the same dose becomes 0.05 mL, and you are now reading 5 units instead of 10 — the same dose at half the resolution.

The underlying point is that vial headspace is the hard constraint. A nominal 2 mL vial typically holds a little over 2 mL to the shoulder; adding 3 mL is not an option and attempting it wastes the lot.

Published content assay results across the independent testing services show nominal and measured content differing by one to ten per cent, which makes content the dominant term in dose error.

Measure a volume you can actually measure. Round numbers, real syringes.

This is the one decision in the whole preparation sequence that cannot be revised later, which is why it is worth thirty seconds of arithmetic.

Dead-space loss scales with the number of draws, not with the concentration, so a lower concentration spread over more draws loses proportionally less of the total peptide.

For a dose that will change during titration, choose the volume for the largest intended dose rather than the first, so the whole schedule fits on one barrel without a mid-vial recalculation.

Nominal vial volumes in the standard 2R and 3R glass sizes have published brimful capacities well above the nominal fill, but the usable volume is bounded by the stopper displacement.

The caveat is that this arithmetic assumes the vial contains what the label says, and without a content assay it is precise about an unknown quantity.

Check the vial can physically hold the volume before you draw it up.

edited 8 May 2026 by e_dziedzic — clarified the distinction between purity and content

Aim for a dose volume somewhere between about 10 and 30 units on a U-100 barrel and the reading problem disappears.

Round to a diluent volume you can measure accurately. Measuring 1.00 mL on a 1 mL syringe is reliable; measuring 1.37 mL on anything is not, and the error propagates into every dose.

Insulin syringe barrel graduations are typically 1 unit on a 0.3 mL barrel, 1 unit on a 0.5 mL barrel and 2 units on a 1 mL barrel, which is why the barrel size changes what is readable.

Nothing here is medical advice, and research-use material is not approved for human use.

Write the concentration on the label at reconstitution, in units per dose.

Put another way, the relevant arithmetic is concentration equals vial content divided by diluent volume, and content is not the same as label claim.

Write the concentration and the resulting units-per-dose on the vial label at reconstitution. The arithmetic that is obvious now will not be obvious at six in the morning three weeks from now.

The general principle here — that peptides adsorb and denature at air–liquid and solid–liquid interfaces — is standard formulation science, and it is why licensed presentations contain a surfactant such as polysorbate 20 or 80. A research vial does not, which is precisely why handling matters more, not less.

A concentration calculated to three decimal places from a diluent volume measured to one is false precision.

Concentration equals content over volume, and content is not label claim.